Elena Perpiñán

Elena Perpiñán

Auto-generated profile, based on publicly available information

Elena Perpiñán

Department of Inflammation Biology, Institute of Liver Studies, School of Immunology and Microbial Sciences, James Black Centre, King's College London, London, SE5 9NU, United Kingdom

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2017 in Liver International
Verified
Journal Article
Closed access
PDF file
SRSergio Rodríguez-Tajes
Sergio Rodríguez-Tajes
EPElena Perpiñán
Elena Perpiñán
BCBerta Caballol
Berta Caballol
SLSabela Lens
Sabela Lens
ZMZoe Mariño
Zoe Mariño
GKGeorge Koutsoudakis
George Koutsoudakis

19 September 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
AKAda Sera Kurt
Ada Sera Kurt
PRPaula Ruiz
Paula Ruiz
ELEmmanuelle Landmann
Emmanuelle Landmann
MEMarwa Elgosbi
Marwa Elgosbi
TFTsz Kan Fung
Tsz Kan Fung
ASAlberto Sanchez-Fueyo
Alberto Sanchez-Fueyo
Conferring alloantigen-specificity to ex vivo expanded CD4+CD25+Foxp3+ Tregs increases their capacity to counteract effector alloimmune responses following adoptive transfer into transplant recipients. Three strategies are currently undergoing clinical development, which involve: 1) expanding Tregs in the presence of donor B cells (donor alloantigen-reactive (DAR-Tregs)); 2) culturing Tregs with donor cells in the presence of co-stimulation blockade (CSB-Tregs); and 3) transducing Tregs with an HLA-A2-specific chimeric antigen receptor (CAR-Tregs). Our goal here was to assess the relative potency of each of these manufactured Treg products both in vitro and in vivo. As compared to polyclonal Tregs, all 3 manufacture strategies increased the precursor frequency of alloreactive Tregs, and this was proportional to the overall in vitro immunosuppressive properties of the cell products. Accordingly, CAR-Tregs, which contained the highest frequency of donor-reactive Tregs, exhibited the strongest suppressive effects on a cell-per-cell basis. Similarly, in an in vivo mouse model of GvHD, infusion of CAR-Tregs conferred a significantly longer recipient survival than any other Treg product. Our results highlighting the alloantigen-reactivity and associated immunosuppressive properties of different manufactured Treg products have implications for the mechanistic interpretation of currently ongoing clinical trials in transplantation.

19 November 2019 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
SRSergio Rodríguez-Tajes
Sergio Rodríguez-Tajes
EPElena Perpiñán
Elena Perpiñán
TLThais Leonel
Thais Leonel
SLSabela Lens
Sabela Lens
ZMZoe Mariño
Zoe Mariño
XFXavier Forns
Xavier Forns

23 August 2018 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
EPElena Perpiñán
Elena Perpiñán
NCNoelia Caro‐Pérez
Noelia Caro‐Pérez
NGNeris García-González
Neris García-González
Josep GregoriJosep Gregori
Josep Gregori
PGPatricia González
Patricia González
SPSofía Pérez-del-Pulgar
Sofía Pérez-del-Pulgar

2 August 2020 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
EPElena Perpiñán
Elena Perpiñán
SPSofía Pérez-del-Pulgar
Sofía Pérez-del-Pulgar
MLMaria Carlota Londono
Maria Carlota Londono
ZMZoe Mariño
Zoe Mariño
SLSabela Lens
Sabela Lens
GKGeorge Koutsoudakis
George Koutsoudakis